Stay updated with breaking news from Mark Lanasa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)Sep 19, 2023 6:00 AMRegulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwideTEVIMBRA is the cornerstone of BeiGene...
BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA®Sep 19, 2023 6:15 AMEuropean Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC)U.S. FDA accepts Biologics License Ap...
The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.
BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.
European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma U.S. FDA accepts Biologics License Application in first-line advanced ESCC ...